Drug

Treprostinil (Tyvaso®)

Status:
Phase 3
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Inhaled Drug
Funder Type:
Industry

Drug Details

Inhaled treprostinil is an inhaled medication approved for the treatment of pulmonary arterial hypertension in World Health Organization (WHO) Group 1 patients. Inhaled treprostinil is a synthetic analogue of prostacyclin, a naturally occurring substance in the body, which has effects on dilating blood vessels. Inhaled treprostinil was approved for PAH by the United States Food and Drug Administration (FDA) in 2009 and for PH-ILD in 2021.

IPF Study Purpose

Study RIN-PF-301 is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute FVC in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period. 

Find a Clinical Trial

PPF Study Purpose

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

Find a Clinical Trial

Latest News on Treprostinil (Tyvaso®)